FDA Approves Pancreatic Enzyme Products to Aid Digestion

02 Mar 2012 --- Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Mar 2 2012 --- Two new pancreatic enzyme products used to help aid food digestion, Ultresa (pancrelipase) and Viokace (pancrelipase), were approved by the U.S. Food and Drug Administration.

Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Viokace, in combination with a proton pump inhibitor, is used to treat adults who cannot digest food normally. Adults with chronic pancreatitis, a continuing, chronic inflammatory process of the pancreas, or those who have had some or all of their pancreases removed (pancreatectomy) may not digest food normally because they lack needed enzymes or because their enzymes are not released into the bowel (intestine). Viokace’s safety and efficacy in children has not been established.

“The approvals of Ultresa and Viokace, along with the other approved pancreatic enzyme products, allow health care providers to prescribe the product that is most appropriate for the estimated 200,000 patients in the United States who have pancreatic insufficiency,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research.

Ultresa and Viokace are the fourth and fifth pancreatic enzyme products approved by FDA. Other FDA-approved pancreatic enzyme products include Creon (2009), Zenpep (2009) and Pancreaze (2010). Approved pancreatic enzyme products meet FDA standards for safety, efficacy and product quality.

Unapproved pancreatic enzyme products had been available for many years. FDA established a date of April 28, 2010 for the makers of pancreatic enzyme products to stop manufacturing and distributing unapproved products.

Ultresa and Viokace are marketed by Bridgewater, N.J.-based Aptalis Pharma U.S. Inc.
 

Related Articles

Business News

Scientists find natural mimetics of anti-cancer and anti-aging drugs

04 Dec 2017 --- Researchers from the Biogerontology Research Foundation in the UK, Insilico Medicine, Life Extension and other institutions have announced the publication of a landmark study in the journal Aging on the identification of natural mimetics of metformin and rapamycin.

Regulatory News

Synthetic antioxidant l-ergothioneine safe as a novel food for pregnant women and children: EFSA

24 Nov 2017 --- The European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and Allergies (NDA) has concluded that synthetic l-ergothioneine is safe under the proposed uses and use levels for the groups of the population which had been excluded by the applicant in the original application. Following a request from the European Commission, EFSA confirmed the safety of the powerful antioxidant for groups including infants, young children (i.e. toddlers), pregnant women and breastfeeding women.

Nutrition & Health News

Low-salt and DASH diet as effective as drugs for some adults with high blood pressure: study

23 Nov 2017 --- A study of adults with prehypertension, or stage 1 high blood pressure, has shown that combining a low-salt diet with the heart-healthy DASH diet substantially lowers systolic blood pressure – the top number in a blood pressure test – especially in people with higher baseline systolic readings.

Nutrition & Health News

Combined resistance to antibiotics a growing problem in EU, say top health officials

15 Nov 2017 --- Over the course of 2016, combined resistance to several antibiotic groups continued to increase for Escherichia coli (E. coli) and Acinetobacter species, which mainly cause healthcare-associated infections such as pneumonia and bloodstream infections. This is according to the European Centre for Disease Prevention and Control’s (ECDC) latest EU-wide data on antibiotic resistance, as well as its guidance on prevention and control of carbapenem-resistant Enterobacteriaceae (CRE). 
 

Regulatory News

Roadmap: Researchers publish recommendations for successful EU health food claims

14 Nov 2017 --- Researchers have developed recommendations to help food companies successfully substantiate new health claims in the EU. During this study, published in the highly regarded Trends in Food Science & Technology, researchers from the University of Surrey worked with investigators in Slovenia and Denmark as part of the REDICLAIM project. Together, they clarified the process of attaining approval for new health claims on food products.

More Articles
URL : http://www.nutritioninsight.com:80/news/FDA-Approves-Pancreatic-Enzyme-Products-to-Aid-Digestion.html